Search the NeLM

Medicines A-Z
Find key information about medicines by name (prototype)
NeLM news service
Horizon scanning: License extension application filed in EU for use of rivaroxaban for stroke prevention in AF patients and further VTE indications

Source: The pharmaletter

Date published: 06/01/2011 17:10

Summary
by: Yuet Wan

Bayer has submitted an application to the European Medicines Agency to extend the license of rivaroxaban to include stroke prevention in patients with atrial fibrillation, and the treatment of deep vein thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism.

Link

Preview your comment

Add new comment

Comment text:

Comments

There are no comments yet. You could be the first! You must be Logged In to comment.
Related news
2.8.2 Oral anticoagulants
24/05/2012
Horizon scanning: FDA advisory panel recommends against approval of rivaroxaban to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome
23/05/2012
NICE issues clinical audit tool to support recommendations for guideline on rivaroxaban for the prevention of stroke and systemic
10/05/2012
License extension application submitted in US for use of rivaroxaban to reduce risk of stent thrombosis in patients with acute coronary syndrome
Arrhythmias
23/05/2012
NICE issues clinical audit tool to support recommendations for guideline on rivaroxaban for the prevention of stroke and systemic
18/05/2012
FDA statement on risk of cardiovascular death linked to azithromycin
17/05/2012
Cohort study: Azithromycin and the risk of cardiovascular death
Stroke
24/05/2012
Recombinant tissue plasminogen activator for acute ischaemic stroke – RCT and systematic review & meta analysis
18/05/2012
Review: Secondary prevention after ischaemic stroke or transient ischaemic attack
03/05/2012
Post-hoc sub-analysis: Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack
Venous Thromboembolism
24/05/2012
RCT: Aspirin for preventing the recurrence of venous thromboembolism – WARFASA trial
23/05/2012
NICE issues clinical audit tool to support recommendations for guideline on rivaroxaban for the prevention of stroke and systemic
21/05/2012
Analysis: Prophylaxis rates for VTE and GI bleeding in general medical patients- too low or too high?
Back